Related by context. All words. (Click for frequent words.) 79 grade cervical intraepithelial 75 CIN2 + 74 precancerous cervical lesions 72 grade cervical dysplasia 71 CIN3 71 CIN2 71 precancerous cervical 71 premalignant lesion 71 histologic subtype 70 neoplasia CIN 70 epithelial tumors 70 precursor lesions 70 cervical lesions 70 situ CIS 69 acute GvHD 69 external genital lesions 69 grade squamous intraepithelial 69 cervical carcinoma 69 intraepithelial neoplasia 69 cervical dysplasia 69 HGPIN 69 dysplastic lesions 69 vaginal lesions 69 advanced adenoma 69 FluCAM arm 69 proctitis 69 gastric adenocarcinoma 68 invasive ductal 68 abnormal cytology 68 ductal cancer 68 ASCUS 67 HBeAg negative 67 endometrial hyperplasia 67 lobular carcinoma 67 MALT lymphoma 67 neoplasias 67 squamous intraepithelial lesions 67 elevated ALT 67 advanced adenomas 67 nonmetastatic 67 adenomatous polyps 67 GISTs 67 urothelial carcinoma 67 basal cell carcinoma BCC 67 chlamydial infection 67 neoplasia 67 hematologic toxicity 67 relapsed MM 67 cervical vulvar 67 onset diabetes mellitus 66 neoplasia PIN 66 epithelial ovarian cancer 66 breast carcinoma 66 astrocytomas 66 histologically confirmed 66 pT2 66 fallopian tube carcinoma 66 anogenital warts 66 Adenomas 66 CIN3 + 66 colorectal adenoma 66 renal scarring 66 breast carcinomas 66 CMV infection 66 HER2 expression 66 recurrent VTE 66 cervical neoplasia 66 Squamous 66 recurrent venous thromboembolism 66 vulvar intraepithelial neoplasia 66 prostate cancer CaP 66 HPV-#/# 66 cutaneous squamous cell carcinoma 66 anal intraepithelial neoplasia 66 leucopenia 65 colorectal carcinoma 65 HER2 overexpression 65 histological subtype 65 PSA nadir 65 leiomyomas 65 overt nephropathy 65 ovarian carcinoma 65 cervical intraepithelial neoplasia CIN 65 serum prostate 65 pCR 65 nodal metastasis 65 epithelial ovarian 65 NMIBC 65 NNRTI resistance 65 ertapenem 65 node metastases 65 SGPT 65 CTAP# Capsules 65 bladder carcinoma 65 recurrent metastatic 65 metastatic gastric 65 biochemical relapse 65 pre cancerous lesions 65 anal cancers 65 CYT# potent vascular disrupting 65 specific antigen PSA 65 adverse reactions incidence 65 intestinal polyps 65 quadrivalent vaccine 65 pT3 65 ara C 65 nonmelanoma skin cancers 65 situ LCIS 64 invasive aspergillosis 64 Follicular Lymphoma 64 ductal carcinomas 64 dermatologic toxicities 64 metastatic malignant 64 complete cytogenetic response 64 neutropaenia 64 Chlamydia infection 64 advanced neoplasia 64 ALT elevation 64 orchitis 64 cutaneous melanoma 64 locoregional recurrence 64 antibody titer 64 glycated hemoglobin levels 64 diabetes mellitus DM 64 PCa 64 genital herpes infections 64 hematopoietic cancers 64 VUR 64 HNSCC 64 #.#ng/ml 64 T1c 64 Chlamydia trachomatis infection 64 S. aureus isolates 64 recurrent UTI 64 endometrial cancers 64 Tindamax R 64 endometriosis ovarian cysts 64 hypercalciuria 64 Invasive Breast Cancer 64 serum testosterone 64 penile cancers 64 metastatic GIST 64 invasive lobular 64 haematologic 64 hyperplasia BPH 64 histologically proven 64 macroalbuminuria 64 Soft Tissue Sarcoma 64 progesterone receptor negative 64 hormone receptor negative 64 gastric carcinoma 64 invasive carcinoma 64 prostate carcinoma 64 latent tuberculosis infection 64 PREZISTA r arm 64 adenomatous 64 urothelial bladder cancer 64 superficial bladder cancer 64 BCG vaccinated 64 endometrial carcinoma 64 atrophic gastritis 64 EBRT 64 metastatic neuroendocrine tumors 64 non metastatic osteosarcoma 64 HBV infection 64 completely resected 64 tumors GIST 64 cTnT 63 CCyR 63 pulmonary metastases 63 skeletal metastases 63 systemic fungal infections 63 renal cell carcinomas 63 oral squamous cell 63 vesicoureteral reflux 63 osteosarcomas 63 dasatinib Sprycel ® 63 grade cervical lesions 63 Acute Myeloid Leukaemia AML 63 BRCA1 mutation carriers 63 leukemia AML 63 severe NCI CTC 63 venous blood clots 63 lymphopenia 63 Papillary 63 cytomegalovirus infection 63 lipid abnormalities 63 â ‰ ¥ 63 HBeAg 63 BCG refractory 63 HBeAg seroconversion 63 cervical abnormalities 63 grade prostatic intraepithelial 63 vaginal cancers 63 resectable 63 ErbB2 positive 63 sustained virological response 63 fallopian tube cancers 63 polyp recurrence 63 tumor histology 63 lobular carcinomas 63 Human papillomavirus 63 anaplastic astrocytomas 63 MCyR 63 alanine aminotransferase ALT 63 CR nPR 63 invasive cervical cancer 63 lobular cancer 63 HPV subtypes 63 grade glioma 63 elevated triglyceride levels 63 atypical hyperplasia 63 colorectal neoplasms 63 carotid stenosis 63 operable breast cancer 63 cervical vaginal 63 febrile neutropenia 63 oncogenic HPV 63 colorectal polyp 63 serous ovarian cancer 63 juvenile idiopathic arthritis JIA 63 amenorrhoea 63 overactive bladder syndrome 63 recurrent glioblastoma multiforme 63 HPV# 63 metachronous 63 cytoreduction 63 myeloproliferative diseases 63 gestational hypertension 63 Human Papillomavirus 63 EGFR HER2 63 hepatitis C genotype 63 Toxicities 63 choriocarcinoma 63 herpes zoster shingles 63 sUA 63 Leukemias 63 Cervista HPV HR 63 cervical cancer precancerous 63 Adjuvant chemotherapy 63 laboratory abnormalities 63 follicular lymphoma FL 63 Mitomycin C 63 stage IIIB 63 chemotherapy induced neutropenia 63 basal cell nevus syndrome 63 B7 H3 63 B Cell Lymphoma 63 MAGE A3 ASCI 63 atypical ductal hyperplasia 63 anal lesions 63 invasive candidiasis 63 Hurthle cell 63 nonvertebral fractures 63 abnormal lipid 63 abnormal pap smears 63 HBsAg 63 nonproliferative 63 p# antigen 63 Pharmacokinetics PK 63 transferrin saturation 63 nonvaccine 63 abnormal Pap smear 63 acute leukemias 63 evaluable subjects 63 primary hyperparathyroidism 63 pediatric malignancies 62 transaminase elevations 62 AGHD 62 HIV uninfected 62 DFMO 62 myeloperoxidase 62 cholangiocarcinoma 62 Human Papillomavirus HPV 62 genital lesions 62 C. trachomatis 62 genital ulcers 62 ug dose 62 LHRH receptor positive 62 BRCA2 mutation carriers 62 undetectable HBV DNA 62 parasitemia 62 hepatocellular carcinomas 62 myelodysplastic syndrome MDS 62 nucleotide analog 62 advanced hepatocellular carcinoma 62 abnormal pap tests 62 hypophosphatemia 62 vWD 62 idiopathic PAH 62 ductal breast cancer 62 Vaccine Recombinant 62 Vicinium TM 62 liver metastasis 62 HBeAg positive patients 62 thromboembolic disease 62 colorectal cancer CRC 62 endometrioid 62 post thrombotic syndrome 62 dysplastic lesions caused 62 biologic DMARD 62 diagnostic biomarker 62 refractory prostate cancer 62 PEG IFN 62 TT genotype 62 biochemical recurrence 62 Epstein Barr virus EBV 62 TNF Tumor Necrosis Factor 62 dose cohort 62 pretest probability 62 dysglycemia 62 adenocarcinomas 62 unresectable tumors 62 bacterial vaginosis BV 62 monoinfected patients 62 lymphovascular invasion 62 prostate adenocarcinoma 62 Trichomonas vaginalis 62 grade dysplasia 62 invasive carcinomas 62 BRAF mutations 62 hemorrhagic complications 62 severe neutropenia 62 colorectal adenomas 62 papillary renal cell carcinoma 62 severe oral mucositis 62 Anaplastic 62 tumor recurrence 62 leukemia ALL 62 KRAS mutations occur 62 ADPKD 62 graft dysfunction 62 cobiprostone 62 H pylori 62 hepatocellular carcinoma HCC 62 pericardial effusion 62 precancerous tumors 62 invasive lobular carcinoma 62 smoldering myeloma 62 squamous cell lung cancer 62 candidemia 62 mRCC 62 adenoma 62 coronary stenosis 62 micafungin 62 S. aureus colonization 62 peripheral sensory neuropathy 62 CIMZIA ™ 62 fluconazole resistant 62 CLL SLL 62 refractory chronic lymphocytic 62 Malignant Melanoma 62 preoperative PSA 62 % Confidence Interval 62 HPV genotypes 62 chorioamnionitis 62 cancerous cervical lesions 62 LTBI 62 baseline LDH 62 corticosteroid dose 62 cytologic 62 hereditary hemochromatosis 62 Naive Patients 62 latent celiac disease 62 chronic periodontitis 62 precancers 62 Cervista HPV 62 bacteriuria 62 x ULN 62 SUVmax 62 hyperphenylalaninemia HPA due 62 PAOD 62 Clostridium difficile infections 62 mesotheliomas 62 obstructive coronary artery 62 Irinotecan 62 parous women 62 distant metastases 62 finasteride Proscar 62 hemorrhagic cystitis 62 malignant lesions 62 ALT flares 62 HCV Genotype 62 prolonged QT interval 62 CMV disease 62 NRTI resistance 62 sero positive 62 curative resection 62 genotypic resistance 62 HIV HCV coinfected 62 BARACLUDE ® 62 mucinous 62 antigen PSA 62 BCR ABL mutations 62 hyperbilirubinemia 62 Human papillomavirus HPV 62 Paraplatin ® 62 metastatic prostate 62 p = #.# [003] 62 nonalcoholic steatohepatitis NASH 62 EXJADE 62 resectable pancreatic cancer 62 CaP 62 trimethoprim sulfamethoxazole 62 urethritis 62 hepatic fibrosis 62 HCV infection 61 liver histology 61 Non Alcoholic Steatohepatitis 61 ALT elevations 61 Human Papilloma Virus HPV 61 testicular tumors 61 renal tumors 61 beta estradiol 61 hypercalcemia 61 serum urate levels 61 chronic HCV infection 61 elevated CRP 61 aspartate aminotransferase 61 pretreatment serum 61 liposomal amphotericin B 61 HbF 61 metastatic lesions 61 LSIL 61 etiologic 61 malignant lymphoma 61 lupus erythematosus 61 mL/min/#.# m 2 61 systolic hypertension 61 distant metastasis 61 hepatorenal syndrome 61 LHRH antagonists 61 Lymphocytic 61 International Prognostic Scoring 61 genotype 1b 61 MGUS 61 bronchopulmonary dysplasia 61 neuroblastoma tumors 61 intraventricular hemorrhage 61 C1 INH deficiency 61 tuberculin skin testing 61 FDG PET imaging 61 varicocele 61 T1DM 61 anti HBs 61 adenoma recurrence 61 serum phosphate 61 peritumoral brain edema 61 myelodysplastic myeloproliferative diseases 61 contralateral breast 61 castrate resistant prostate cancer 61 System IPSS 61 contrast induced nephropathy 61 microscopic hematuria 61 PSADT 61 adjunctive placebo 61 ovarian cervical 61 hypereosinophilic syndrome 61 Candida infections 61 human papillomaviruses HPV 61 signal transduction inhibitors 61 CP CPPS 61 transitional cell carcinoma 61 asthma rhinitis 61 Response Evaluation Criteria 61 neutropenic fever 61 lymphocytosis 61 trichomonas 61 HER2 positive cancers 61 Doxil ® 61 acute myeloid 61 peritoneal cancer 61 non splenectomized 61 definite stent thrombosis 61 juvenile idiopathic arthritis 61 Clusterin 61 oesophageal adenocarcinoma 61 N. gonorrhoeae 61 VivaGel ™ 61 recurrent genital herpes 61 refractory NSCLC 61 Haptoglobin 61 bladder cancers 61 vertebral fracture 61 leukopenia 61 ECOG PS 61 Nilotinib 61 intestinal metaplasia 61 HeFH 61 BRCA mutation carriers 61 cervical adenocarcinoma 61 Aspergillus infections 61 abnormal Pap smears 61 squamous 61 Ozarelix 61 atherogenic dyslipidemia 61 recurrent DVT 61 Folfox 61 Hepatitis B Virus 61 deep venous thromboses 61 metastatic pancreatic 61 overt hepatic encephalopathy HE 61 breast endometrial 61 varices 61 BRACAnalysis ® 61 GABHS 61 simplex virus 61 receiving Vectibix monotherapy 61 hormone receptor status 61 BCG refractory carcinoma 61 Human Papilloma Virus 61 Janus kinase 61 pmol L 61 ocular toxicity 61 hepatic cirrhosis 61 platelet reactivity 61 familial hypercholesterolemia 61 IgG antibody 61 PCNSL 61 tuberous sclerosis TS 61 dasatinib Sprycel 61 erlotinib Tarceva ® 61 variceal bleeding 61 abnormal Pap 61 BRCA deficient 61 Glioblastoma Multiforme 61 alanine aminotransferase 61 thromboembolic events 61 hypovitaminosis D 61 maternal serum 61 anal HPV 61 aspartate aminotransferase AST 61 neoplasm 61 Bronchiectasis 61 thromboembolic complications 61 thrombocytopenia neutropenia 61 oral antidiabetic medication 61 candidiasis 61 receptor tyrosine kinase inhibitor 61 acute humoral rejection 61 dexamethasone Decadron 61 metastatic colorectal 61 Leydig cell 61 ABCB1 61 oral allopurinol 61 Non Alcoholic Fatty 61 thromboembolic 61 prostate cancer PCa 61 confidence interval #.#-#.# 61 Stage IIB 61 subependymal giant cell 61 recurrent preterm birth 61 mg/m2 dose 61 log# reduction 61 PEGylated anti 61 lobular breast cancer 61 complement inhibitor eculizumab 61 IgA antibodies 61 alpha1 antitrypsin deficiency 61 nasopharyngeal carcinoma 61 malignant polyps 61 Venous thromboembolism 61 Human papilloma virus 61 cisplatin chemotherapy 61 SPIRIVA ® 61 CTAP# 61 atypical hemolytic uremic syndrome 61 aminotransferase ALT 61 squamous cell cancers 61 astrocytoma 61 underwent resection 61 2 methoxyestradiol 61 FOLFOX6 61 chlamydial infections 61 neuroendocrine carcinoma 61 cervical cancer precursors 61 5 Fluorouracil 61 ribavirin therapy 61 Elagolix 61 VivaGel TM 61 elevated bilirubin 61 thyroid nodules 61 benign proliferative breast 61 proliferative retinopathy 61 response CCyR 61 5-FU/LV 61 Thromboembolism 61 seropositivity 61 lipohypertrophy 61 SSc 61 HSV2 61 precancerous lesions 61 % CI #.#-#.# [007] 61 HbA 1c levels 61 hepatocellular carcinoma liver 61 sodium glucose cotransporter 61 tamoxifen Nolvadex ® 61 mutated K ras 61 E selectin 61 lymph node metastasis 60 gonococcal infection 60 M#V mutation 60 clodronate 60 cytogenetic response 60 Retreatment 60 rebleeding 60 caspofungin 60 leiomyoma 60 NNT = 60 breast abscesses 60 microalbuminuria 60 cervical cytology 60 grade gliomas 60 sarcomatoid 60 Onychomycosis 60 certolizumab 60 squamous cell carcinoma SCC 60 fetal aneuploidy 60 #q# deletion syndrome 60 urine cytology 60 novel VDA molecule 60 testicular germ cell 60 intravesical therapy 60 hydroxymethyl coenzyme 60 recurrent ovarian 60 ovarian endometrial 60 HBV infections 60 hematologic abnormalities 60 Pegylated Interferon 60 Gorlin syndrome 60 dysuria 60 anterior uveitis 60 prednisone prednisolone 60 neurofibromas 60 neutrophil count 60 neuroendocrine cancers 60 tumor lysis syndrome 60 ano genital warts 60 follicular lymphomas 60 nephrotoxicity 60 prostatic hyperplasia 60 Adjuvant Treatment 60 mg BID dose 60 Interferon Beta 60 gynecologic malignancy 60 subclinical hypothyroidism 60 neoplastic lesions 60 Hematologic 60 prostate pancreatic 60 K ras mutations 60 TNF blocker therapy 60 ACAPODENE TM 60 geographic atrophy 60 bladder ovarian 60 carcinoma HCC 60 chlamydial 60 octreotide LAR 60 colorectal carcinomas 60 DLTs 60 immunocompetent patients 60 Vidaza ® 60 myelofibrosis polycythemia vera 60 HES CEL 60 acute GVHD 60 Xyfid TM 60 Uterine cancer 60 posterior uveitis 60 benign noncancerous 60 Cardiotoxicity 60 aminotransferase levels 60 non squamous NSCLC 60 Endometrial 60 Tumor Necrosis Factor 60 Prostatic 60 severe rotavirus gastroenteritis 60 chronic prostatitis 60 quadrivalent human papillomavirus 60 hormone receptor positive 60 CCR5 tropic HIV 60 pheochromocytoma 60 STRIDE PD 60 ovarian tumors 60 gastrointestinal stromal tumors GIST 60 solar keratoses 60 lowest tertile 60 tPSA 60 hydronephrosis 60 smoldering multiple myeloma 60 undergone radical prostatectomy 60 Androgen deprivation therapy 60 peritoneal carcinomatosis 60 extracapsular extension 60 % CI #.#-#.# [003] 60 gastric cardia 60 papillary thyroid carcinoma 60 pancreatic lung 60 Cerebril TM 60 cell lymphoma CTCL 60 prior chemotherapy regimens 60 indinavir 60 Chronic Prostatitis 60 Ishak fibrosis score 60 imatinib Gleevec ® 60 CIMZIA TM certolizumab pegol 60 essential thrombocythemia 60 Hormone Refractory Prostate Cancer 60 pelvic lymphadenectomy 60 penile anal 60 Hepatocellular Carcinoma HCC 60 pertuzumab 60 TRAIL R1 60 testicular cancers 60 breast uterine 60 chlamydia infection 60 G6PD deficiency 60 recurrent wheezing 60 Kinoid 60 clinically detectable 60 pulmonary metastasis 60 esophageal squamous cell carcinoma 60 GARDASIL ® 60 mucosal inflammation 60 Ductal carcinoma 60 SRBD 60 osteopenic 60 prognostic indicator 60 DAS# CRP 60 risk HPV genotypes 60 S. aureus infections 60 oral prodrug 60 neovascular 60 Stomatitis 60 virological failure 60 refractory gout 60 MDS MPD 60 Partial Response 60 Xanafide 60 targeted radiotherapeutic 60 thyroglobulin 60 LV dysfunction 60 antibody titers 60 protease inhibitor PI 60 resistant hormone refractory 60 treat benign prostatic 60 erosive gastritis 60 lopinavir r arm 60 subclinical atherosclerosis 60 HPV infections 60 Heavy menstrual bleeding 60 choroidal neovascularization 60 Helicobacter pylori infection 60 delayed CINV 60 Alkaline Phosphatase 60 reactogenicity 60 careHPV 60 proteinuria 60 postoperative chemotherapy 60 Immunohistochemical staining 60 neutropenia dehydration dyspnea 60 AAT deficiency 60 Basal Cell 60 latent tuberculosis TB 60 albumin excretion rate 60 essential thrombocythemia ET 60 Renal Cell Carcinoma RCC 60 CC genotype 60 chemotherapy cisplatin 60 pelvic malignancies 60 VTEs 60 axillary node 60 sensory neuropathy 60 Postoperative complications 60 metastatic bladder 60 COPD exacerbation 60 prognostic indicators 60 malignant neoplasm 60 somatostatin analog 60 Dasatinib 60 anthracycline taxane 60 complete cytogenetic 60 urinary bladder cancer 60 differentiated thyroid 60 % CI #.#-#.# [008] 60 vaccinees 60 chronically immunosuppressed solid 60 tumor xenograft models 60 abacavir Ziagen 60 LNG IUS 60 hypercholesterolaemia 60 POAG 60 CrCl 60 bacteraemia 60 Factor Receptor 60 superficial basal cell carcinoma 60 immunocompetent 60 radical prostatectomy RP 60 conventional cytology 60 venous thromboembolic events 60 genital ulcer disease 60 interferon γ 60 Advanced Renal Cell 60 autoantibody positive 60 acne vulgaris 60 Carcinoma 60 systemic lupus erythematosus SLE 60 T1a 60 ribavirin RBV 60 forodesine 60 HER2 negative 60 pre cancerous 60 mediastinitis 60 non alcoholic steatohepatitis 60 NATRECOR ® 60 hemodynamically significant 60 virological response 60 thrombotic complications 60 Amgen Neulasta R 60 neoplasms 60 intracranial hemorrhage ICH 60 leukemia CLL 60 cough dyspnea 60 diaper dermatitis complicated 60 chronic eosinophilic leukemia 60 ritonavir boosted 60 undergoing radical prostatectomy 60 cell adhesion molecule 60 cervical precancer 60 % CI #.#-#.# [004] 60 Neoadjuvant 60 mycophenolate mofetil 60 precancer 60 dacarbazine DTIC 60 PegIFN RBV 60 recurrent miscarriage 60 antibody MAb 60 fetal malformations 60 seminoma 60 prognostic variables 60 Nonalcoholic fatty liver 60 nucleoside analogues 60 basal cell cancers 60 pathophysiological effects 60 chronic HBV 60 benign breast 60 sustained virologic response 60 mcg dL 60 thromboses 60 esophagitis 60 arterial thromboembolic events 60 colonic polyps 60 colorectal adenocarcinoma 60 immunomodulatory therapy 60 alemtuzumab treated 60 Febrile neutropenia 60 alkylating agent 60 gastrointestinal malignancies 60 perianal 60 chronic hepatitis cirrhosis 60 cisplatin resistant 60 fluorouracil leucovorin 60 androgen deficiency 60 Metastases 60 taxane resistant 60 budesonide foam 60 Bezielle 60 Angiotensin converting enzyme 60 partial remissions 60 sorafenib tablets 60 anemia hemoglobin 60 hepatocellular carcinoma 60 Peginterferon Alfa 2a 60 H. pylori eradication 60 diagnosing coronary artery 60 neutrophil counts 60 gestational diabetes mellitus 60 gastrointestinal toxicities 60 monoclonal antibody conjugated 60 BEXXAR Therapeutic Regimen 59 cisplatin gemcitabine 59 G#DT 59 decompensated liver disease 59 ancrod 59 bacterial prostatitis 59 Catheter Associated 59 ZACTIMA 59 chronic HBV infection 59 IgA deficiency 59 erythematosus 59 visceral metastases 59 mmol liter 59 lomitapide 59 mIU ml 59 nodal metastases 59 HBeAg negative patients 59 biopsy Gleason 59 apolipoprotein B 59 Candida infection 59 DVT PE 59 adjunctive screening 59 bullous 59 Staphylococcus aureus infections 59 recurrent NSCLC 59 Legg Calvé Perthes disease 59 Inhibin B 59 anthracycline containing 59 INCB# [003] 59 rheumatoid factor 59 ductal lobular 59 Non inferiority 59 Adenocarcinoma 59 aplastic anemia AA 59 immunohistochemical 59 total thyroidectomy 59 lung pancreatic 59 enteroviral infection 59 antiphospholipid syndrome 59 precancerous condition 59 recurrent glioma 59 lipid elevations 59 GSTP1 59 nonalcoholic steatohepatitis 59 neoadjuvant 59 Asymptomatic 59 TGFBR1 * 6A 59 nonnucleoside reverse transcriptase inhibitors 59 uterine cervix 59 type 1diabetes 59 gastrointestinal perforation 59 familial hypercholesterolemia FH 59 thyroid peroxidase 59 OGTT 59 alpha1 antitrypsin AAT deficiency 59 acid phosphatase PAP 59 edifoligide 59 hyperparathyroidism 59 thromboembolism 59 lactate dehydrogenase LDH 59 pancreatic prostate 59 refractory cutaneous T 59 mitochondrial toxicity 59 bronchoalveolar lavage 59 endocrine therapies 59 deletion 5q 59 Respiratory Syncytial Virus RSV 59 Familial Adenomatous Polyposis FAP 59 allograft rejection 59 Human Papillomavirus Quadrivalent Types 59 IELT 59 unresectable stage 59 galiximab 59 hematological parameters 59 Severe Primary IGFD 59 cranial irradiation 59 Herpes simplex virus 59 Hyperlipidemia 59 thyroid carcinoma 59 elevated serum creatinine 59 serum creatinine levels 59 BRCA2 carriers 59 systemic anaplastic large 59 Surgical resection 59 clinically localized prostate 59 pancreatic adenocarcinoma 59 Ophena TM 59 Decitabine 59 inhibitor RG# 59 variceal hemorrhage 59 LymphoStat B belimumab 59 papillary 59 metastatic malignant melanoma 59 AA Amyloidosis 59 intact parathyroid hormone 59 cytological 59 chlorambucil 59 parasitaemia 59 idiopathic myelofibrosis 59 IFN beta 59 PCA3 scores 59 seminal vesicle invasion 59 Cholinesterase Inhibitors 59 bladder tumors 59 serogroup B 59 intravascular hemolysis 59 castrate resistant 59 Epstein Barr Virus EBV 59 ALT normalization 59 HCV genotype 59 thyrotropin 59 Omacetaxine 59 TEAEs 59 monocytic 59 sCJD 59 malignant ascites 59 HER2 amplification 59 transgene expression 59 progesterone receptor 59 lupus anticoagulant 59 polycythemia vera essential thrombocythemia 59 Pneumocystis carinii pneumonia